Clinical trial · Observational
DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.
NCT07717437CI-TRIAL-00118717recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The DRAGON registry aims to collect data on combined portal and hepatic vein embolization (PVE/HVE) for liver tumors, a technique expected to enhance liver regeneration compared to standard PVE. This collaborative registry focuses on identifying associations between baseline clinical/imaging parameters, clinical outcomes, and safety for patients undergoing PVE/HVE.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Cancer | Malignant Liver Neoplasm | CURATED_EXACT | 0.92 |
| Liver Metastases | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- PVE/HVE
- description
- This registry collects data on patients who have undergone combined portal and hepatic vein embolisation prior to major liver surgery.
Primary outcomes (1)
- measure
- Resectability three weeks after PVE/HVE and 5 years overall survival
- timeFrame
- From enrolment until 5 year follow up
Secondary outcomes (10)
- measure
- Number of complications during embolization
- timeFrame
- Perioperative
- description
- The number of complications occurring during liver embolization (e.g., spill to the future liver remnant).
- measure
- Kinetic Growth Rate [%/week]
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who have undergone PVE/HVE or technical variations on this procedure * 18 Years and older * Men and women
References
Publications (8)
- BACKGROUNDJames S, van der Leij C, van Dam RM, Detry O. Liver venous deprivation before major hepatectomy-promising but still a work in progress. Hepatobiliary Surg Nutr. 2026 Feb 1;15(1):10. doi: 10.21037/hbsn-2025-560. Epub 2026 Jan 12. No abstract available. PMID 41676779
- BACKGROUNDJames S, Smits J, van der Velden AL, Simon SR, Korenblik R, Dewulf MJL, van Dam RM, van der Leij C; DRAGON Trials Collaborative. Invited Commentary on "CIRSE Standards of Practice on Portal Vein Embolization and Double Vein Embolization/Liver Venous Deprivation". Cardiovasc Intervent Radiol. 2024 Sep;47(9):1311-1312. doi: 10.1007/s00270-024-03815-9. Epub 2024 Jul 29. No abstract available. PMID 39078494
- BACKGROUNDKorenblik R, Heil J, Smits J, James S, Olij B, Bechstein WO, Bemelmans MHA, Binkert CA, Breitenstein S, Williams M, Detry O, Dewulf MJL, Dili A, Grochola LF, Grote J, Heise D, Kalil JA, Metrakos P, Neumann UP, Pappas SG, Pennetta F, Schnitzbauer AA, Tasse JC, Winkens B, Olde Damink SWM, van der Leij C, Schadde E, van Dam RM; DRAGON trials collaborative. Liver regeneration after portal and hepatic vein embolization improves overall survival compared with portal vein embolization alone: mid-term survival analysis of the multicentre DRAGON 0 cohort. Br J Surg. 2024 Apr 3;111(4):znae087. doi: 10.1093/bjs/znae087. PMID 38662462
- BACKGROUNDKorenblik R, van der Leij C, van Dam RM. Reply to: Portal and Hepatic Vein Embolization to Accelerate Future Liver Remnant Hypertrophy-The Road Towards Level One Evidence. Cardiovasc Intervent Radiol. 2023 Jan;46(1):166-167. doi: 10.1007/s00270-022-03271-3. Epub 2022 Sep 20. No abstract available. PMID 36127520
- BACKGROUNDKorenblik R, van Zon JFJA, Olij B, Heil J, Dewulf MJL, Neumann UP, Olde Damink SWM, Binkert CA, Schadde E, van der Leij C, van Dam RM; DRAGON Trials Collaborative. Resectability of bilobar liver tumours after simultaneous portal and hepatic vein embolization versus portal vein embolization alone: meta-analysis. BJS Open. 2022 Nov 2;6(6):zrac141. doi: 10.1093/bjsopen/zrac141. PMID 36437731